Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 29 01:00PM ET
2.44
Dollar change
+0.03
Percentage change
1.24
%
Index- P/E- EPS (ttm)-0.57 Insider Own0.54% Shs Outstand37.10M Perf Week-2.01%
Market Cap90.52M Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float36.91M Perf Month-18.39%
Income-21.25M PEG- EPS next Q-0.11 Inst Own42.03% Short Float0.12% Perf Quarter-32.60%
Sales67.04M P/S1.35 EPS this Y1.40% Inst Trans-4.10% Short Ratio0.41 Perf Half Y-58.99%
Book/sh1.38 P/B1.77 EPS next Y21.24% ROA-22.13% Short Interest0.05M Perf Year-52.06%
Cash/sh0.87 P/C2.80 EPS next 5Y3.00% ROE-35.41% 52W Range2.27 - 8.50 Perf YTD-53.79%
Dividend Est.- P/FCF- EPS past 5Y-113.97% ROI-38.77% 52W High-71.29% Beta0.33
Dividend TTM- Quick Ratio1.80 Sales past 5Y7.38% Gross Margin40.33% 52W Low7.49% ATR (14)0.19
Dividend Ex-Date- Current Ratio2.45 EPS Y/Y TTM-14.21% Oper. Margin-32.26% RSI (14)41.92 Volatility6.97% 7.62%
Employees307 Debt/Eq0.11 Sales Y/Y TTM11.26% Profit Margin-31.70% Recom1.00 Target Price10.45
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-28.36% Payout- Rel Volume0.55 Prev Close2.41
Sales Surprise-17.82% EPS Surprise-11.70% Sales Q/Q9.40% EarningsNov 07 BMO Avg Volume111.21K Price2.44
SMA20-4.44% SMA50-8.54% SMA200-50.99% Trades Volume61,235 Change1.24%
Date Action Analyst Rating Change Price Target Change
Nov-01-22Initiated Jefferies Buy $11
Apr-28-21Initiated Piper Sandler Overweight $13
Apr-15-20Initiated B. Riley FBR Buy $5.50
Jul-28-14Downgrade Northland Capital Outperform → Market Perform $6 → $3.50
Jun-16-14Initiated H.C. Wainwright Buy $6
Mar-05-13Initiated Northland Capital Outperform $6
Nov-18-10Reiterated Morgan Joseph Buy $3 → $5.25
Aug-20-09Reiterated Roth Capital Hold $2.50 → $5
Nov-24-08Reiterated Roth Capital Hold $2.50
Mar-26-08Reiterated Roth Capital Hold $6 → $4.50
Nov-27-24 07:00AM
Nov-22-24 08:00AM
Nov-19-24 08:00AM
Nov-08-24 06:02AM
Nov-07-24 07:00AM
08:00AM Loading…
Nov-06-24 08:00AM
07:50AM
Oct-30-24 01:01AM
Oct-24-24 08:00AM
Oct-01-24 07:00AM
Sep-19-24 08:00AM
Aug-29-24 08:00AM
Aug-28-24 07:00AM
Aug-07-24 07:00AM
Aug-06-24 07:00AM
06:33AM Loading…
Jul-22-24 06:33AM
Jul-19-24 04:15PM
Jul-08-24 07:00AM
Jun-03-24 08:00AM
May-22-24 08:00AM
May-17-24 08:10AM
May-16-24 12:52PM
08:00AM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-23-24 08:00AM
Mar-29-24 09:44AM
Mar-27-24 11:53AM
07:00AM
Mar-13-24 07:00AM
07:00AM Loading…
Mar-06-24 07:00AM
Mar-04-24 07:00AM
Feb-29-24 07:00AM
Feb-01-24 08:00AM
Jan-08-24 08:00AM
Jan-02-24 08:00AM
Dec-12-23 08:00AM
Dec-06-23 04:30PM
Nov-30-23 08:00AM
Nov-20-23 08:00AM
Nov-10-23 03:33PM
Nov-09-23 06:00AM
Nov-06-23 08:00AM
Oct-26-23 08:00AM
Sep-06-23 08:00AM
Aug-25-23 09:06AM
Aug-24-23 06:30AM
Aug-10-23 08:00AM
Jul-26-23 08:00AM
Jul-06-23 11:05AM
Jun-09-23 10:37AM
May-24-23 08:00AM
May-17-23 06:30AM
May-05-23 01:33PM
May-03-23 08:00AM
Apr-21-23 08:00AM
Apr-10-23 08:00AM
Apr-06-23 08:00AM
Apr-05-23 07:44PM
Mar-30-23 06:30AM
Mar-24-23 06:30AM
Mar-21-23 04:30PM
Mar-10-23 08:12AM
Mar-09-23 08:00AM
Feb-14-23 09:00AM
Jan-31-23 08:00AM
Jan-21-23 09:29AM
Jan-05-23 08:00AM
Dec-31-22 09:03AM
Dec-23-22 11:43PM
Dec-10-22 08:17AM
Dec-06-22 08:00AM
Nov-30-22 04:01PM
08:50AM
Nov-22-22 08:42AM
Nov-21-22 10:00AM
08:00AM
07:10AM
Nov-16-22 04:35PM
Nov-15-22 09:40AM
Nov-14-22 08:36AM
Nov-10-22 08:50AM
Nov-03-22 06:07AM
Nov-02-22 08:00AM
Nov-01-22 05:22PM
Oct-27-22 09:40AM
Oct-24-22 08:50AM
Oct-11-22 09:40AM
Sep-27-22 02:33PM
Sep-26-22 08:00AM
Sep-22-22 08:54PM
04:01PM
Aug-30-22 09:40AM
08:50AM
Aug-25-22 08:47AM
Aug-24-22 04:35PM
Aug-03-22 08:00AM
Aug-01-22 08:50AM
Jul-28-22 09:40AM
Jul-19-22 08:24AM
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LANCE WILLSEYDirectorNov 26 '24Proposed Sale2.4730,00074,160Nov 26 04:28 PM
WILLSEY LANCEDirectorNov 25 '24Proposed Sale2.5022,70256,743Nov 25 06:24 PM
LANCE WILLSEYDirectorNov 22 '24Proposed Sale2.5511,38829,068Nov 22 04:43 PM
LANCE WILLSEYDirectorNov 21 '24Proposed Sale2.4810,00024,841Nov 21 04:47 PM
LANCE WILLSEYDirectorNov 20 '24Proposed Sale2.5320,00050,546Nov 20 04:12 PM
LANCE WILLSEYDirectorNov 19 '24Proposed Sale2.4615,01036,925Nov 19 04:52 PM
LANCE WILLSEYDirectorNov 18 '24Proposed Sale2.4720,00049,410Nov 18 04:42 PM
LANCE WILLSEYDirectorNov 15 '24Proposed Sale2.5221,00052,920Nov 15 04:24 PM
LANCE WILLSEYDirectorNov 14 '24Proposed Sale2.5610,00025,620Nov 14 04:54 PM
LANCE WILLSEYDirectorNov 13 '24Proposed Sale2.589,90025,523Nov 13 04:20 PM